GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India

Completed

Conditions: Hepatitis B
Hepatitis C

First Posted Date: 2013-01-21

Last Posted Date: 2015-07-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 1000

Registration Number: NCT01772121

Locations: 🇮🇳
Civil Hospital, Dawrpui, Aizawl, Mizoram, India
🇮🇳
Dharamsi Hospital,Chandni Chowk, South Shivajinagar, Sangli, Mahashtra, India
🇮🇳
Manipal Hospitals,98, HAL Airport Road, Bangalore, Karnataka, India

and more 16 locations

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Simtuzumab placebo
Drug: Simtuzumab

First Posted Date: 2013-01-16

Last Posted Date: 2017-05-30

Lead Sponsor: Gilead Sciences

Target Recruit Count: 544

Registration Number: NCT01769196

Locations: 🇺🇸
Sarasota Memorial Hospital, Sarasota, Florida, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 171 locations

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection

Phase 3

Completed

Conditions: Chronic Hepatitis C Virus

Interventions: Drug: LDV/SOF
Drug: RBV

First Posted Date: 2013-01-15

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 441

Registration Number: NCT01768286

Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Simtuzumab

First Posted Date: 2013-01-03

Last Posted Date: 2017-04-04

Lead Sponsor: Gilead Sciences

Target Recruit Count: 34

Registration Number: NCT01759511

Locations: 🇺🇸
Arizona Pulmonary Specialists, Ltd., Scottsdale, Arizona, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 3 locations

Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: GS-5806
Drug: Placebo

First Posted Date: 2012-12-27

Last Posted Date: 2015-08-21

Lead Sponsor: Gilead Sciences

Target Recruit Count: 140

Registration Number: NCT01756482

Locations: 🇬🇧
Retroscreen Virology, London, United Kingdom

Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age

Completed

Conditions: Respiratory Syncytial Virus Infections

First Posted Date: 2012-12-21

Last Posted Date: 2013-08-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 2432

Registration Number: NCT01754428

Locations: 🇺🇸
Pediatrics & Adolescent Medicine, P.A., Marietta, Georgia, United States
🇺🇸
Kentucky Pediatric/Adult Research, Bardstown, Kentucky, United States
🇺🇸
Advanced Pediatrics, Vienna, Virginia, United States

and more 12 locations

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

Phase 1

Completed

Conditions: Chronic Hepatitis C Virus

Interventions: Drug: Velpatasvir
Drug: Placebo

First Posted Date: 2012-12-04

Last Posted Date: 2020-12-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 103

Registration Number: NCT01740791

Locations: 🇺🇸
West Coast Clinical Trials, LLC, Costa Mesa, California, United States
🇺🇸
Avail Clinical Research, LLC, DeLand, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

and more 6 locations

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Phase 3

Terminated

Conditions: Indolent Non-Hodgkin's Lymphomas

Interventions: Drug: Placebo
Drug: Rituximab
Drug: Idelalisib

First Posted Date: 2012-11-26

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 295

Registration Number: NCT01732913

Locations: 🇺🇸
Cancer Center of Santa Barbara, Santa Barbara, California, United States
🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸
Saint Jude Heritage Healthcare, Fullerton, California, United States

and more 100 locations

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Phase 3

Terminated

Conditions: Indolent Non-Hodgkin's Lymphomas

Interventions: Drug: Idelalisib
Drug: Rituximab
Drug: Bendamustine
Drug: Placebo

First Posted Date: 2012-11-26

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 475

Registration Number: NCT01732926

Locations: 🇨🇦
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
🇺🇸
Cancer Center of Kansas, Wichita, Kansas, United States
🇮🇹
Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy

and more 138 locations

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

Phase 1

Terminated

Conditions: Non-hodgkin's Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: IMMU-114

First Posted Date: 2012-11-19

Last Posted Date: 2021-08-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 30

Registration Number: NCT01728207

Locations: 🇺🇸
Huntsman Cancer Institute, Univ. Utah, Salt Lake City, Utah, United States
🇺🇸
Helen F Graham Cancer Center, Newark, Delaware, United States
🇺🇸
Indiana University Health Goshen Hospital, Goshen, Indiana, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy